领先的生物技术研究公司
EBITDA
TBD
Gross
TBD
Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
© 2026 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://dev.cherrycoding.com/mergerscorp/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
生物技术企业,拥有 2500 多例临床治疗的良好安全记录。 公司设计、制造和销售亲和血液过滤产品。 这是一种高度创新的新型血液过滤装置,它采用已获专利的专有生物仿生 ...
这家待售的美国主机托管公司主要提供共享主机、域名、VPS 和专用计划。 公司主要为美国、西欧和加拿大客户提供 VPS 和共享主机服务。 公司提供极具竞争力的价格以及包 ...
该公司于 10 多年前在英国成立。它专注于网络安全、托管和商业智能。公司在全球拥有服务器,包括伦敦、洛杉矶、芝加哥、法兰克福、圣保罗、约翰内斯堡、多伦多、阿姆 ...
2021 年,全球护肤品市场规模达 1,358.5 亿美元。 护肤品作为一个细分市场,其增长速度超过了美容业的任何其他领域。 去年,美国的护肤品销售额增长了 13%。 在此期间,在 ...
在美国出售的企业,寻找在美国出售的最佳成熟企业,在美国出售的企业市场,在美国购买企业,在美国出售的企业,为美国的企业家发现机会,在美国出售的公司 . 浏览可立即购买的最佳美国待售企业、美国待售小型企业、探索美国待售企业、美国待售企业机会。
生物技术企业,拥有 2500 多例临床治疗的良好安全记录。 公司设计、制造和销售亲和血液过滤产品。 这是一种高度创新的新型血液过滤装置,它采用已获专利的专有生物仿生技术,可快速清除血液感染患者体内的细菌、真菌、细菌毒素、病毒、促炎细胞因子和败血症介质。
投资呼吁
全球受败血症影响的患者数以百万计,败血症市场每年约有 3000 万例病例。
这项技术的其他应用还包括:作为生物武器攻击(COVID)的应对措施、PDAC 癌症、防止在诊断、血库和生物处理中使用 ECMO 和心肺旁路时产生的副作用。
到 2028 年底,该公司的估值将达到 400 亿美元,仅为追踪净利润的 10 倍。
发展机遇
强有力的管理
毛利率>85
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
This website is operated by MergersUS Inc a US Corporation with registered office at




